• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Buspirone: Still Effective After All These Years?

Buspirone: Still Effective After All These Years?

February 3, 2021
Eugene Rubin, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Eugene Rubin, MD. Psychiatrist in private practice, Bingham Farms, MI. Dr. Rubin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

When buspirone was released in 1986, it was advertised as providing “a different kind of calm.” Unfortunately, physicians and their patients weren’t ready to accept the kind of calm that required several weeks to take effect, when punchier, quicker benzos were the standard route to tranquility. Although buspirone is FDA approved for generalized anxiety disorder (GAD), some question whether it treats anxiety at all. In this article, we will look at how buspirone works and what it can and can’t do for our patients.

How buspirone works
Buspirone, an azapirone, is in a class of its own. It was a failed antipsychotic before it was shown to be effective for GAD. Its primary mechanism of action is 5HT1A partial agonism, which is a component of the mechanism in the antidepressant vilazodone and a few antipsychotics (aripiprazole, brexpiprazole, cariprazine, clozapine, and quetiapine). Buspirone’s other mechanisms, which include mild D2 antagonism and noradrenergic effects, are less understood.

What it can and can’t do
Buspirone clearly works in GAD, but does it work as well as other treatments? In a meta-analysis of studies in patients with GAD, its effect size was smaller (0.17) than that of other GAD meds, such as SSRIs (0.36) and benzodiazepines (0.38) (Hidalgo RB et al, J Psychopharmacol 2007;21(8):864–872). On the other hand, buspirone has held up well in head-to-head comparisons with multiple benzodiazepines, and patients do just as well when switched from benzodiazepines to buspirone (Delle Chiaie R et al, J Clin Psychopharmacol 1995;15(1):12–19). Its other advantages include lack of dependence, tolerance, withdrawal, and abuse potential. It does not impair cognition or increase the risk of falls.

Buspirone is popular as an augmentation strategy in major depression, although the evidence for its role there is tenuous. It ranked below lithium, the atypical antipsychotics, and thyroid augmentation in a meta-analysis, and bupropion outperformed it in the augmentation phase of the STAR*D trial. To its favor, buspirone did work better in severe depression in a large randomized augmentation trial, and it may be worth trying when tolerability is the priority (Zhou X et al, J Clin Psychiatry 2015;76(4):e487–e498; Appelberg BG et al, J Clin Psychiatry 2001;62(6):448–452). Buspirone may also relieve two common side effects of SSRIs: sexual dysfunction and bruxism (Garrett AR and Hawley JS, Neurol Clin Pract 2018;8(2):135–141).

Buspirone does not treat depression on its own, but an intriguing pilot study suggests it may work as an antidepressant when combined with melatonin. The trial was inspired by animal research, where low-dose buspirone had neuroprotective effects when combined with melatonin, but not on its own. In the multicenter placebo-controlled trial of 132 patients with acute major depression that followed, buspirone 15 mg + melatonin sustained-release 3 mg qhs, but not buspirone alone, improved depression and cognition with a moderate effect size (0.43) (Fava M et al, J Psychiatr Res 2012;46(12):1553–1563).

Buspirone may relieve physical and psychological symptoms of premenstrual dysphoric disorder, according to small controlled trials that either dosed it continuously or in the 2 weeks before menses (10–30 mg/day) (Nazari H et al, Arch Gynecol Obstet 2013;287(3):469–472). It may also have anti-aggressive effects in various populations, including dementia, traumatic brain injury (TBI), mental retardation, and children with ADHD or oppositional defiant disorder (Cantillon M et al, Am J Geriatr Psychiatry 1996; 4(3):263–267). Jonathan Silver, MD, editor of the APA textbook on TBI, uses buspirone first-line for irritability and aggression in TBI at doses up to 30 mg bid (See TCPR, Aug 2020).

Buspirone failed as an antipsychotic, but the doses used in those studies (up to 1,200 mg/day) confirmed its safety, and open-label studies suggest high doses (up to 180 mg/day) improve tardive dyskinesia (Moss LE et al, J Clin Psychopharmacol 1993;13(3):204–209). Buspirone has been extensively tested in alcoholism, where the best that can be said is that it helped subjects’ anxiety but not their addiction. Studies in cocaine and nicotine dependence were also negative. Buspirone does not work in social anxiety or panic disorder, and studies in OCD are inconclusive.

When and how to use it
Buspirone is a good choice when tolerability is needed, whether for GAD or antidepressant augmentation. More challenging is starting buspirone in patients with a history of benzodiazepine use. There the dosage needs to be primed with psychoeducation, emphasizing its lack of tolerance, withdrawal, and cognitive side effects. Help the patient understand that while they may be giving up the rewarding effect, the antianxiety effects of buspirone will be comparable to benzos in the long term.

I usually start with 5–7.5 mg bid and raise to 15 mg bid over a week. From there, I’ll let it rest 2–4 weeks to determine its efficacy and raise as needed. Buspirone is licensed up to a max of 60 mg/day, and some authors go up to 90 mg/day for anxiety. With its 3-hour half-life, tid dosing is usually recommended, but one study found equal benefit with bid dosing—much more feasible for many patients (Sramek JJ et al, Depression and Anxiety 1999;9(3):131–134).

Buspirone is a substrate of CYP3A4, so you will want to use higher doses in patients on inducers such as carbamazepine and lower doses in patients on inhibitors such as fluvoxamine, nefazodone, or grapefruit juice. Taking it with food can increase its absorption up to 2-fold and reduce nausea. Other side effects to watch for are headache and dizziness. In bipolar disorder, buspirone can rarely induce mania.

TCPR Verdict: When patients need a tolerable medication for GAD that lacks sexual side effects and has no potential for tolerance or abuse, buspirone is first-line. For antidepressant augmentation, buspirone is not clearly effective, but it can be used when tolerability is the main concern.

Table: Buspirone at a Glance


Table: Buspirone at a Glance


(Click to view full-size PDF.)



podcastsTo learn more, listen to our 2/22/21 podcast, “Does Buspirone + Melatonin = An Antidepressant?” Search for “Carlat” on your podcast store.

General Psychiatry
KEYWORDS anxiety anxiety disorders benzodiazepines buspirone gad generalized-anxiety-disorder lavender medication melatonin pharmacology pregnancy psychopharmacology silexan
    Eugene Rubin, MD.

    Locked-In Syndrome and Quality of Life

    More from this author
    www.thecarlatreport.com
    Issue Date: February 3, 2021
    SUBSCRIBE NOW
    Table Of Contents
    How to Come Off a Psych Med Part 1: Antipsychotics
    Stimulants and Creativity
    Does Abilify cause more weight gain than Seroquel?
    Are SSRIs Associated With Increased Rates of Violence?
    How to Switch Antipsychotics
    Roundup
    Buspirone: Still Effective After All These Years?
    CME Post-Test - Stopping Psych Meds Part 1, TCPR, February 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2603816031.jpg
      General Psychiatry

      A Scam for Every Woman, Child, and Man: Part 2

      1 in 3 Americans were victims of online scams in the past year. Even when you know your patient is being scammed, it is hard to pull them out. We speak with Cathy Wilson about...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.